GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Short-Term Debt

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Short-Term Debt : €28.6 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt?

Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt for the quarter that ended in Jun. 2024 was €28.6 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly Short-Term Debt declined from Jun. 2023 (€23.5 Mil) to Dec. 2023 (€22.7 Mil) but then increased from Dec. 2023 (€22.7 Mil) to Jun. 2024 (€28.6 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual Short-Term Debt increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€17.2 Mil) and increased from Dec. 2022 (€17.2 Mil) to Dec. 2023 (€22.7 Mil).


Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Short-Term Debt
- - 17.15 22.71

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Short-Term Debt Get a 7-Day Free Trial 8.09 17.15 23.49 22.71 28.64

Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Biocytogen Pharmaceuticals (Beijing) Co Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines